Amarantus to Present at Upcoming Investor Conferences SAN

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Amarantus to Present at Upcoming Investor Conferences

SAN FRANCISCO, Aug. 19, 2014 (GLOBE NEWSWIRE) -- Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that Gerald Commissiong, President and CEO, is scheduled to present to investors at the 16th Annual Rodman & Renshaw Healthcare Conference to be held September 8-10, 2014 at the New York Palace Hotel in New York City. The presentation is scheduled for Tuesday, September 9th at 2:30 PM ET and will be web cast live, please visit the Company's IR Events section to participate. Additional information about the conference can be found at http://www.rodm.com/ .

Mr. Commissiong is also scheduled to present at the Aegis Capital Healthcare and Technology Conference to be held at the Wynn Las Vegas on September 10-13, 2014. His presentation will take place on Thursday, September 11 th at 2:30 PM PT. Conference information may be found at   http://www.meetmax.com/sched/event_25932/~pub...t_id=25932 .

Amarantus will also be participating in the First Annual Zacks Healthcare Meetup on Monday, September 8th.

Attendees who wish to meet with management one on one may contact the conference organizers or our Investor Relations department at  ir@amarantus.com . 

About Amarantus

Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. The Company has licensed Eltoprazine a phase 2b ready indication for Parkinson's Levodopa induced dyskinesia. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). For further information please visit  www.Amarantus.com , or connect with the Company on  Facebook , LinkedIn ,  Twitter  and  Google+ .

Investor/Media Contacts Aimee Boutcher Director of Investor Relations Amarantus Bioscience Holdings, Inc. 408-737-2734 x 101

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Everest Group Faces Shaky Ground in Securities Fraud Suit

Updated Category News Views 128

Investors Take Aim at Everest Group's Alleged Missteps Looks like Everest Group, Ltd. (NYSE: EG) has found itself knee-deep in legal quicksand. There's a class-action lawsuit afoot, spearheaded by the folks at Schall, Brown & Schwartz LLP. They're putting forward claims that Everest, a player in the securities exchange, was painting a misleading picture when it came to...

Continue Reading
Doppel's Strategic Expansion: Adding PropRise Innovators

Updated Category News Views 62

Doppel Boosts Its Team with PropRise Founders The market doesn’t lie: when a company's on a roll, you watch it closely. Doppel's latest move is a serious signal. They've snagged PropRise, a sprightly Y Combinator graduate, and landed its founders, Jean-Michael Diei and Matthew Krager, right into their engineering fold. These guys aren't greenhorns—cutting their teeth...

Continue Reading
Johnsonville's Election Effort: Sausage for Dinner Gains Momentum

Updated Category News Views 88

Sausage Politics: A Tasty New Agenda Well, ain't that something? A sausage campaign running parallel to the midterms wasn't exactly on my bingo card. But here we are, America, dealing with a 'Sausage Tsunami.' This cheeky strategy from Johnsonville sure packs a punch, leveraging electoral fatigue to put sausage right where they want it: on your dinner plate. The Campaign...

Continue Reading
Silvercorp Updates El Domo Budget Amid Challenges

Updated Category News Views 141

Budget Pains for Silvercorp's El Domo Project Folks, if you thought navigating the stock market was a minefield, try mining these days. Silvercorp Metals Inc. had to bump up its budget for the El Domo project in Ecuador—again. This time by $14.6 million. What's causing this fiscal heartache? Everything from rising diesel prices thanks to Ecuador playing games with...

Continue Reading
Historic Surge: Women Veterans Join 120th Congress

Updated Category News Views 107

The Winds of Change Are Blowing Through Washington It looks like the face of Congress is getting a combat-ready makeover with the latest election results. Veterans are stepping up to the plate, claiming at least 79 seats in the 120th Congress, with a historic presence of women veterans making waves. Yeah, we're talking about 11 women veterans hitting the halls of power,...

Continue Reading
Life with PAH: A Journey of Awareness and Hope

Updated Category News Views 230

Unearthing the Hidden Struggle of PAH The American Lung Association (ALA) is getting loud about a quiet killer—pulmonary arterial hypertension (PAH) is in their spotlight this month, and it's about time. Documenting the horror stories of some 500 to 1,000 new PAH diagnoses each year in the U.S., the ALA is peeling back the blinds on a condition that's too often...

Continue Reading
The Braff Group's 400th Health Care M&A Milestone

Updated Category News Views 31

No one just stumbles into 400 successful deals without a whole lot of grit, especially in the gnarly jungle of health care services mergers and acquisitions. The Braff Group, a stalwart in this arena since 1998, has just hit this remarkable milestone. If you ask me, this isn't just a number—it's a testament to the blood, sweat, and relentless dedication poured into...

Continue Reading
Citius Unveils Promising LYMPHIR Data at EORTC Conference

Updated Category News Views 77

A Closer Look at LYMPHIR's Impact on CTCL Patients Well, here's a whiff of genuine hope for folks grappling with relapsed or refractory cutaneous T-cell lymphoma (CTCL). Coming out of New Jersey, Citius Oncology has dished out some pretty promising news, fresh from the European Organisation for Research and Treatment of Cancer Cutaneous Lymphoma Tumour Group's annual...

Continue Reading
Webull Corp Caught in Legal Storm; Investors Take Note

Updated Category News Views 87

A Legal Storm Brewing It's like walking into a saloon, expecting a smooth drink, only to find a bar fight breaking out in front of you. That's the scene with Webull Corporation (NASDAQ: BULL) right now. This time, they ain't just shooting the breeze; they're in the line of legal fire. SBS Law, a heavyweight in shareholder rights, is rallying the troops for a class action...

Continue Reading
NACCO Navigates Strong 2026 Q3, Faces Solar Cost Hurdles

Updated Category News Views 34

Rolling With NACCO's Financial Punches Well, folks, when it rains, it pours—numbers that is. NACCO Industries just laid out their Q3 results for all to gawk at, and it's a mixed bag of triumphs and tussles. You got a gross profit of $11.8 million, a sweet 18% jump on the same quarter last year. Now, you're talking about revenue muscle, and there it is. Income before...

Continue Reading

Top 5 Most Recently Viewed Articles

Alex Bastian Named VP of Commercial Strategy at Memo Therapeutics

Updated Category News Views 282

Alex Bastian Appointed as VP of Commercial Strategy at Memo Therapeutics AG Memo Therapeutics AG (or “MTx”), a late-stage biotech firm committed to transforming unique human immune responses into effective treatments for viral infections and cancer, has announced the appointment of Alex Bastian as its new VP of Commercial Strategy. Expertise in the Biotech Industry...

Continue Reading
Understanding Alliant Energy's Rising Short Interest Insights

Updated Category News Views 282

Alliant Energy's Rising Short Interest Alliant Energy's short percent of float has recently increased, reaching 9.49% since the last report. The energy provider has reported a total of 7.74 million shares sold short. This accounts for about 3.46% of its total available shares for trading, indicating an active trading environment. Understanding Short Interest Short...

Continue Reading
China's 2024 Fiscal Revenue: A Shift Towards Proactive Measures

Updated Category News Views 270

China's Fiscal Revenue Growth and Economic Challenges In recent reports, it's shown that China's fiscal revenue in 2024 has seen an increase of 1.3% year on year. This rate of growth is a significant decline from the 6.4% expansion recorded in 2023. The slowdown in revenue has raised concerns amid economic uncertainties. The Impact of the Property Market One of the...

Continue Reading
Troomi CEO Bill Brady Strengthens Commitment to Youth Mental Health

Updated Category News Views 542

Troomi CEO Bill Brady Strengthens Commitment to Youth Mental Health In a significant step forward for youth mental health advocacy, Bill Brady, the CEO of Troomi Wireless, has been appointed to the Board of Directors of Speak Our Minds, a nonprofit organization dedicated to combatting the youth mental health crisis. This collaboration aims to unite technology with a...

Continue Reading
Investigation of Investors' Claims Against Unisys Corporation

Updated Category News Views 467

Rosen Law Firm Investigates Claims for Unisys Corporation Investors Rosen Law Firm, a well-respected global investor rights organization, is currently conducting an investigation concerning potential securities claims on behalf of shareholders of Unisys Corporation (NYSE: UIS). This investigation arises from serious allegations suggesting that Unisys might have provided...

Continue Reading